Peter Keeling of Diaceutics
In the Company of Mavericks
00:00
What Are the Risks on the R&D Side?
Peter Cevallos: I'm always asking the questions about how fast, how quick, when. He says legacy pharma-facing tech service businesses are looking at precision medicine and saying we want to be a part of that. That's an admirable ambition but you can't just throw money up and then switch on tomorrow morning, he says. "You have to really work and mine" in order to make sure those things are in the right place,"Cevallos adds.
Transcript
Play full episode
